Koru Med Sys Stock Price, News & Analysis

KORU Medical Systems (NASDAQ: KRMD) announced the appointments of Rob Cannon as Vice President of Sales and Brian Hertzog as Vice President of BioPharma Business Development. Cannon will focus on U.S. sales and enhancing subcutaneous therapy penetration, while Hertzog will drive biopharmaceutical business development and new drug integration. CEO Linda Tharby emphasized the company's growth potential and expertise in large-volume subcutaneous infusion solutions, backed by FDA and CE regulatory clearances. This leadership expansion aims to accelerate growth and meet the significant unmet needs in the biopharmaceutical market.

KORU Medical Systems (NASDAQ: KRMD) will report its third quarter 2021 financial results on November 10, 2021. Management will host a conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can access the call via designated phone numbers based on location or via the company's Investor section. The archived webcast will be available for six months post-event, allowing stakeholders to stay informed about KORU Medical's performance and updates.

Repro Med Systems, Inc., operating as KORU Medical Systems (NASDAQ: KRMD), announced the appointment of Chris Pazdan as Vice President of Quality Assurance and Regulatory Affairs. Mr. Pazdan brings over 16 years of experience from notable companies such as Hillrom and Abbott Laboratories. His expertise in quality and regulatory strategy aims to strengthen KORU Medical's Quality Management System to meet global standards. CEO Linda Tharby emphasized Mr. Pazdan's strategic and operational skills as key assets for the company's growth in meeting biopharmaceutical customer needs.

KORU Medical Systems (NASDAQ: KRMD) reported second-quarter 2021 results with net revenue of $5.5 million, reflecting a 28.3% decline year-over-year but a 2% sequential increase. The gross margin was 58.1%, down 5.6 percentage points from last year, influenced by lower volumes. The company reported a net loss of $1.1 million or $(0.03) per diluted share, unchanged from Q2 2020. Despite these challenges, CEO Linda Tharby noted a rebound in the subcutaneous immunoglobulin market and a focus on growth strategies for their SCIg therapy franchise.

KORU Medical Systems (NASDAQ: KRMD) will participate in Canaccord Genuity’s 41^st Annual Growth Conference on August 12, 2021, at 3:00 PM EDT. The event highlights the company’s focus on developing specialty infusion solutions aimed at improving patient quality of life.

Management's presentation can be accessed live or in archive for six months via the Investors section of KORU Medical’s website.

KORU Medical Systems (NASDAQ: KRMD) plans to report its second quarter 2021 financial results on August 11, 2021. The management will hold a conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial outcomes and present a corporate update. Interested parties can participate via a U.S. toll-free number or an international line, using conference ID 13721184. A webcast will be available on KORU Medical's website for six months post-event.

KORU Medical Systems (NASDAQ: KRMD) reported its Q1 2021 results, revealing net revenue of $5.4 million, a 14% decline from $6.3 million in Q1 2020, attributed mainly to decreased sales in novel therapies and pandemic impacts. Gross margin stood at 59.5%, consistent with last year. The company incurred a net loss of $1.3 million, or $(0.03) per diluted share, primarily due to leadership change expenses. Total operating expenses rose to $5.4 million, up from $3.2 million the previous year. Adjusted EBITDA was $(0.4) million, a decrease from $1.3 million in Q1 2020.

KORU Medical Systems (NASDAQ: KRMD) will announce its Q1 2021 financial results on May 12, 2021. The results will be discussed during a conference call at 4:30 p.m. ET, providing an opportunity for management to give updates on the company’s performance and future plans. KORU Medical specializes in specialty infusion solutions that enhance the quality of life for patients. Their product line includes the FREEDOM Syringe Infusion System, designed for home and alternate care settings.

KORU Medical Systems reported its financial results for Q4 and full year 2020, revealing a net revenue of $24.2 million, a 4.4% increase from 2019. The gross margin decreased to 62%, while the company faced a net loss of $1.2 million. Q4 2020 net revenue was $4.1 million, a 34.8% decline from Q4 2019, attributed to precautionary inventory purchases and lower international sales. KORU ended the year with $27.3 million in cash. The company expects Q1 2021 net sales of at least $5.0 million as they focus on growth strategies under new CEO, Linda Tharby.